Tcwp LLC Abb Vie Inc. Transaction History

Tcwp LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$154.79 - $180.76 $48,758 - $56,939	315 Added 12.02%	2,936 $503,000
Q1 2024 May 14, 2024	BUY	$159.82 - $182.1 $479 - $546	3 Added 0.11%	2,621 $477,000
Q4 2023 Feb 14, 2024	SELL	$137.6 - $154.97 $2.13 Million - $2.4 Million	-15,477 Reduced 85.53%	2,618 $405,000
Q3 2023 Oct 24, 2023	BUY	$133.59 - $154.65 $29,924 - $34,641	224 Added 1.25%	18,095 $2.7 Million
Q2 2023 Aug 11, 2023	SELL	$132.51 - $164.9 $16,166 - $20,117	-122 Reduced 0.68%	17,871 $2.41 Million
Q1 2023 May 15, 2023	SELL	$144.61 - $166.54 $491,240 - $565,736	-3,397 Reduced 15.88%	17,993 $2.87 Million
Q4 2022 Feb 13, 2023	SELL	$138.31 - $165.87 $175,930 - $210,986	-1,272 Reduced 5.61%	21,390 $3.46 Million
Q3 2022 Nov 14, 2022	BUY	$134.21 - $153.93 $121,594 - $139,460	906 Added 4.16%	22,662 $3.04 Million
Q2 2022 Aug 15, 2022	SELL	$137.62 - $174.96 $14,174 - $18,020	-103 Reduced 0.47%	21,756 $3.33 Million
Q1 2022 May 10, 2022	BUY	$131.98 - $163.75 $317,015 - $393,327	2,402 Added 12.35%	21,859 $3.54 Million
Q4 2021 Jun 13, 2022	BUY	$107.43 - $135.93 $2.09 Million - $2.64 Million	19,457 New	19,457 $2.63 Million

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Tcwp LLC, based on Form 13F filings with the SEC.

Stay updated on Tcwp LLC with notifications on news.